Promotional interactions between clinicians and pharmaceutical companies are probably associated with harmful outcomes, ...

Generic drugmaker Viatris is beefing up its pain medicine portfolio with a $1.65 billion deal to buy Pacira BioSciences and ...

With the FDA approval of Zenbexus this summer, Bristol Myers Squibb checked off two notable ‘firsts,’ scoring the inaugural ...

Just shy of two months after teeing up its FcRn blocker Vyvgart Hytrulo for entry into another potential immunology niche, ...

Pfizer bagged a coveted first-line maintenance approval for Tukysa. In combination with HER2 antibody drugs, the treatment ...

London-based women’s health pharma Theramex has agreed to pay up to $250 million to license Shanghai-based Asieris’ first-in-class non-surgical treatment for cervical precancerous lesions associated ...

As the Trump administration advances plans to bring its “most favored nation” drug pricing model to Medicare Part B, the ...

A U.K. drug marketing watchdog has slammed CSL Seqirus for “multiple and prolonged deficiencies” in its systems, governance ...

After facing a setback in Germany late last year, Merck & Co.’s European marketing plans for its below-the-skin Keytruda SC are growing more complicated. | After facing a setback in Germany late last ...

A little over a year after landing its flagship approval in chronic hives, Novartis’ oral BTK inhibitor Rhapsido is expanding ...

The National Fragility Index, launched by the API Innovation Center, warns that more than 550 million prescriptions filled in the U.S. in 2023 were for drugs ranked as having high or severe ...

NBA Champion Karl-Anthony Towns knows both ball and COVID-19. | New York Knicks champ Karl-Anthony Towns is sharing his personal experience with COVID to encourage others to talk with their doctors ...